Empress Therapeutics
Signal active
Organization
Contact Information
Overview
Empress Therapeutics is a biotechnology business in its early stages focused on drug development and new molecular insights into health and illness. The company's proprietary bio platform uses evolution, human molecular and genetic data, and artificial intelligence to identify advanced starting points in endogenous drug-like molecules, allowing clinicians to treat a wide range of serious unmet medical needs with small-molecule drug candidates.
About
Industries
Biotechnology, Medical, Product Research
Founded
2022
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Empress Therapeutics headquartered in United States, North America, operates in the Biotechnology, Medical, Product Research sector. The company focuses on Biotechnology and has secured $600.0M in funding across 12 round(s). With a team of 11-50 employees, Empress Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Empress Therapeutics, raised $50.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
1
Investors
1
Lead Investors
0
Total Funding Amount
$50.0M
Details
0
Empress Therapeutics has raised a total of $50.0M in funding over 0 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|
Investors
Empress Therapeutics is funded by 4 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Douglas Cole | - | FUNDING ROUND - Douglas Cole | 50.0M |
| Noubar Afeyan | - | FUNDING ROUND - Noubar Afeyan | 50.0M |
| Empress Therapeutics | - | FUNDING ROUND - Empress Therapeutics | 50.0M |
| Flagship Pioneering | - | FUNDING ROUND - Flagship Pioneering | 50.0M |
Recent Activity
There is no recent news or activity for this profile.